Back

Does dulaglutide impact a composite outcome reflecting atherosclerosis? A post-hoc analysis of the REWIND trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Diabetes and the Heart 3 Diabetes and the Heart ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Giulia Ferrannini

Karolinska Institute, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Comparison of mechanistic pathways of metabolic bariatric surgery in diabetic patients
Doctor N. Chew (Singapore, SG)
Abstract Slides
Presentation thumbnail
The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial
Mr N. Mohammadnia (Nijmegen, NL)
Abstract Slides
Presentation thumbnail
Causes of excess mortality in diabetes patients without coronary artery disease
Doctor K. Olesen (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Association of hepatic steatosis with subclinical cardiac dysfunction in asymptomatic people with type 2 diabetes
Doctor J. Yeo (Leicester, GB)
Abstract Slides
Presentation thumbnail
Non-dipping heart rate & major adverse cardiovascular events in type 2 diabetes mellitus
Doctor L. Vassallo (Msida, MT)
Abstract Slides

Access the full session

Session thumbnail
Diabetes and the Heart 3

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Cardiovascular risk reduction: should we target pre-diabetes?
thumbnail
Congress Presentation
Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting
thumbnail
Congress Presentation
Diabetes as a major comorbidity in heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources